The mean ± SD or median (range) values of the CDAI for patients with CD, the partial mayo score for patients with UC, the ASDAS for patients with SpA with predominant axial involvement, the DAPSA for patients with SpA with predominant peripheral involvement and for patients with PsA, the DAS28-CRP for patients with RA and the PASI and PGA for patients with PsO are reported before and after switching (at the end of the follow up period) in Tables 4–6. This evidence concerns the gene CRP and rheumatoid arthritis.